drugset / Trial / NCT03096834

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

NCT03096834

Phase 3 Completed 246 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have failed other preventive migraine treatments.

Timeline

Start
2017-03-20
Primary completion
2018-01-18
Completion
2021-01-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody 140 mg Subcutaneous

Indications